IQVIA Holdings Inc. (NYSE:IQV) Stock Holdings Boosted by Pine Valley Investments Ltd Liability Co

Pine Valley Investments Ltd Liability Co lifted its position in IQVIA Holdings Inc. (NYSE:IQV) by 62.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 15,392 shares of the medical research company’s stock after buying an additional 5,911 shares during the period. Pine Valley Investments Ltd Liability Co’s holdings in IQVIA were worth $3,025,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of IQV. Capital Performance Advisors LLP bought a new stake in IQVIA in the third quarter worth about $27,000. Synergy Asset Management LLC acquired a new position in shares of IQVIA in the 4th quarter worth approximately $33,000. Avior Wealth Management LLC lifted its stake in IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares during the last quarter. Assetmark Inc. increased its holdings in shares of IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after buying an additional 196 shares in the last quarter. Finally, Concord Wealth Partners bought a new stake in shares of IQVIA during the 3rd quarter worth $57,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Stifel Nicolaus cut their target price on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Leerink Partners restated an “outperform” rating and set a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. BTIG Research cut shares of IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. UBS Group reduced their price target on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Finally, William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $251.22.

IQVIA Stock Up 1.9 %

Shares of IQVIA stock opened at $194.71 on Tuesday. The stock has a 50-day simple moving average of $199.52 and a 200-day simple moving average of $215.96. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The firm has a market cap of $34.29 billion, a price-to-earnings ratio of 25.96, a P/E/G ratio of 1.99 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director John G. Danhakl purchased 1,275 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The stock was bought at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the purchase, the director now owns 1,275 shares in the company, valued at $255,739.50. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.